Ambry Genetics Corporation (Ambry), a leader in clinical genetic diagnostics, announced that Linh H. Le will serve as Ambry’s new Chief Operating Officer (COO). Linh’s primary role will be to develop a scalable operational strategy as Ambry expands its reach globally, following a successful acquisition by Konica Minolta.
Konica Minolta closed its acquisition of Ambry in late October, with a mission to combine the companies’ technologies into a global solution for precision medicine. Mr. Le will contribute heavily towards ensuring Ambry’s operations are well-prepared to achieve that goal.
Linh brings more than 25 years of work experience, stemming from several industry sectors including medical devices, biopharmaceutical, entertainment and management advisory services. Mr. Le spent the last 14 years in the healthcare industry overseeing financial operations at Medtronic’s Diabetes Intensive Insulin Business Unit. Prior to that, Linh held leadership roles at the Walt Disney Company, PricewaterhouseCoopers, Twentieth Century Fox and KPMG.
In his role as Chief Operating Officer, Mr. Le will provide leadership, management and guidance to the senior leadership team on all matters relating to the financial strategy and operations of the organization.
For more information about Ambry Genetics, visit ambrygen.com.
){kind=link}